A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
收藏DataCite Commons2025-06-01 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009830/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants
with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at
least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares
regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and
atezolizumab monotherapy.
提供机构：
Vivli
创建时间：
2024-02-22
